Scientists at Georgia State University have unveiled promising research on an experimental oral antiviral medication, GHP-88310, which has demonstrated a remarkable ability to prevent the spread of a measles-mimicking virus in ferrets. The study, meticulously detailed in the scientific journal Nature Microbiology, focused on canine distemper virus (CDV) as a proxy for measles due to its analogous disease progression in ferrets. This innovative compound proved effective in interrupting transmission through both direct physical contact and airborne routes, suggesting a significant potential for preemptive intervention against viral outbreaks.
The breakthrough research stems from the collaborative efforts within the Center for Translational Antiviral Research (CTAR) at Georgia State. The team’s investigations centered on the capacity of GHP-88310 to act as a prophylactic agent, administered either shortly before or immediately after exposure to the virus. Their findings indicate that the drug successfully arrested transmission pathways, a critical development for public health strategies aimed at containing infectious diseases. Beyond its preventative capabilities, the antiviral also proved instrumental in reducing the period during which infected animals remained contagious, a crucial factor in mitigating the duration and impact of an outbreak.
Richard Plemper, a distinguished Regents’ Professor and director of CTAR, underscored the critical importance of rapid intervention in controlling measles outbreaks. "The swift containment of measles outbreaks is paramount to reasserting control over this persistent virus," Professor Plemper stated. He highlighted that the recent development of GHP-88310, as presented in this study, offers a compelling addition to existing methods, potentially augmenting traditional ring vaccination strategies. The drug’s mechanism of action targets the viral polymerase, an essential enzyme responsible for viral replication, thereby inhibiting the virus’s ability to multiply and spread within a host.
The urgency for such advancements is starkly illustrated by the resurgence of measles across North America. Since 2025, the United States has grappled with thousands of measles infections, resulting in hundreds of hospitalizations and a tragic toll of three confirmed fatalities. Neighboring countries, Canada and Mexico, have also experienced significant outbreaks, marked by multiple deaths, casting a shadow of doubt over the region’s hard-won measles elimination status. This renewed global challenge underscores the imperative for novel therapeutic and preventative tools to combat a disease that was once thought to be on the brink of eradication.
Carolin Lieber, the lead author of the study and a senior postdoctoral fellow in Professor Plemper’s laboratory, expressed considerable enthusiasm regarding the drug’s efficacy in a simulated airborne transmission scenario. "We were incredibly encouraged to observe that oral administration of GHP-88310 completely prevented airborne transmission in our ferret model of measles," Dr. Lieber remarked. She emphasized the groundbreaking nature of this finding, particularly for a viral polymerase inhibitor, and underscored the drug’s exceptional antiviral potency. The ability to effectively block airborne spread is a significant leap forward, as this is a primary mode of transmission for highly contagious respiratory viruses like measles.
To closely mirror real-world transmission dynamics, the researchers engineered a sophisticated experimental setup. This controlled environment allowed for the simulation of both direct physical contact between infected and uninfected ferrets and their cohabitation within shared airspace, thereby excluding any physical interaction. This meticulous design aimed to replicate the multifaceted ways in which viruses can spread within human populations.
Professor Plemper elaborated on the study’s design, explaining its intent to simulate viral dissemination in settings ranging from intimate household environments to more communal spaces like classrooms. "We specifically designed the study to recapitulate viral spread between individuals experiencing direct contact, as might occur within a household, and between individuals with more distant social interactions, such as those found in classrooms or other indoor environments where people are in proximity but not in direct contact," he explained. The implications of GHP-88310 extend beyond mere prevention; when administered therapeutically, it also shortened the duration of illness in their animal model. Professor Plemper posited that if these results translate to human hosts, the drug could substantially alleviate the severe social and economic disruptions associated with prolonged patient quarantine and significantly bolster overall outbreak management strategies.
The promising results from these preclinical trials have paved the way for the next critical phase: formal clinical testing. The research team is actively preparing GHP-88310 for human trials, a crucial step in determining its safety and efficacy in patients. This transition from laboratory research to human clinical investigation marks a significant milestone in the drug development pipeline, offering tangible hope for a new weapon against measles and potentially other viral pathogens.
The collaborative nature of this research is highlighted by the contributions of several other scientists from the Center for Translational Antiviral Research within Georgia State’s Institute for Biomedical Sciences. Josef Wolf, Claire Ruckel, and Lauren Harrison played integral roles in the study’s execution and data analysis. Funding for this groundbreaking work was provided by the National Institute of Allergy and Infectious Diseases (NIAID), a vital component of the National Institutes of Health (NIH), underscoring the national importance placed on combating infectious diseases. The successful progression of GHP-88310 toward clinical trials represents a beacon of progress in the ongoing global effort to control and ultimately eliminate preventable diseases like measles.
About the Author
